Osage University Partners is among the investors in Northwestern spinout Vanqua Bio’s $85m series B round.

Vanqua Bio, a US-based developer of treatments for neurodegenerative diseases based on research at Northwestern University, emerged yesterday with $85m in series B funding backed by spinout-focused venture capital firm Osage University Partners. Omega Funds led the round, which also included OrbiMed, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax and Logos Capital as well as…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.